Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study to Assess KN3835 in the Treatment of Flexible/Semi-Flexible Hammertoe (HMT)
Sponsor: Endo USA Inc., a Keenova Therapeutics Company
Summary
The primary purpose of this study is to assess the efficacy, safety, and tolerability of KN3835 compared to placebo in the treatment of flexible/semi-flexible HMT.
Official title: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of KN3835 vs Placebo in the Treatment of Flexible/Semi-Flexible Hammertoe
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
554
Start Date
2026-08-11
Completion Date
2027-12
Last Updated
2026-09-14
Healthy Volunteers
No
Interventions
KN3835
Participants will receive KN3835.
Placebo
Participants will receive placebo matching to KN3835.
Locations (7)
Keenova Site-009
Corona, California, United States
Keenova Site-008
Tarzana, California, United States
Keenova Site-004
Pinellas Park, Florida, United States
Keenova Site-007
Sweetwater, Florida, United States
Keenova Site-003
Bedford, Texas, United States
Keenova Site-002
McAllen, Texas, United States
Keenova Site-006
Salt Lake City, Utah, United States